Phio Pharmaceuticals to Present at ASCO Annual Meeting

Marlborough, Massachusetts, May 23, 2024 – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a biotechnology firm specializing in clinical-stage treatments, has announced an update on its main clinical candidate, PH-762. The company’s innovative INTASYL™ siRNA gene-silencing technology aims to enhance the efficacy of immune cells in targeting tumor cells. This update will be presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Illinois.

Phio’s latest report covers the completion of the initial dosing cohort in an ongoing open-label Phase 1b clinical trial (NCT 06014086). The study is focused on assessing the safety and tolerability of intratumoral administration of PH-762 in patients with cutaneous squamous cell carcinoma (cSCC), melanoma, and Merkel cell carcinoma. Notably, Stages 1 and 2 cSCC account for 77% of all new cSCC cases annually, and currently, there are no approved drug treatments for these stages.

"We are excited to share the progress of our trial with the oncology community," stated Mary Spellman, M.D., the acting Chief Medical Officer of Phio. "We believe that this immuno-oncology therapy could provide significant clinical benefits to patients while reducing the need for surgical procedures."

Presentation Details:
- Title: INTASYL™ PH-762: PD-1 Intratumoral Immunotherapy for Cutaneous Carcinoma
- Poster Number: TPS9620
- Topic: Melanoma/Skin Cancer
- Presenting Author: Mary Spellman, M.D.
- Date and Time: June 1, 2024, from 1:30 PM to 4:30 PM CDT

About Phio Pharmaceuticals Corp.:
Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company focused on developing therapies that enhance immune cell function to combat tumors. The company’s proprietary INTASYL™ RNAi technology is uniquely positioned as the only self-delivering RNAi platform dedicated to immuno-oncology. The technology targets specific proteins that hinder the body's cancer-fighting capabilities without necessitating special formulations or delivery systems.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!